Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial

2021733 citationsJournal Articlegreen Open Access

Authors

Ben M. Eyck · Erasmus MC

J. Jan B. van Lanschot · Erasmus MC

Maarten C.C.M. Hulshof · Amsterdam University Medical Centers

Berend J. van der Wilk · Erasmus MC

Joël Shapiro · Erasmus MC

Pieter van Hagen · Erasmus MC

Mark I. van Berge Henegouwen ·

Abstract

The overall survival benefit of patients with locally advanced resectable esophageal or junctional cancer who receive preoperative chemoradiotherapy according to CROSS persists for at least 10 years.

Topics & Keywords

Esophageal Cancer Research and Treatment Esophageal and GI Pathology Gastric Cancer Management and Outcomes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 39, Issue 18, pp. 1995-2004

DOI: 10.1200/jco.20.03614

Field-Weighted Citation Impact: 104.91